Roche’s Alecensa Goes Up Against Zykadia with First-Line NSCLC US FDA Approval

Expanded US approval for Alecensa in ALK-positive NSCLC will stand the product in good stead as it helps make up for upcoming biosimilar threat to Avastin, Rituxan and Herceptin.